Source comparison
TB-500 Studied Tendon Injury: Comparison
Mechanism of Action Promotes actin polymerization, upregulates VEGF, suppresses MMP-9 Activates FAK-paxillin pathway, enhances angiogenesis, modulates nitric oxide Delivers concentrated growth factors (PDGF, TGF-β, IGF-1) directly to tissue Causes controlled i
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Promotes actin polymerization, upregulates VEGF, suppresses MMP-9
- Activates FAK-paxillin pathway, enhances angiogenesis, modulates nitric oxide
- Delivers concentrated growth factors (PDGF, TGF-β, IGF-1) directly to tissue
- Causes controlled inflammation to stimulate healing response
- TB-500 and BPC-157 target specific molecular pathways; PRP delivers broad growth factors; prolotherapy is entirely mechanical
- Animal Study Evidence
- 40–60% faster healing in equine SDFT injuries; 43% greater tensile strength in rat Achilles models
- Accelerated healing in rat Achilles transection models; improved ligament strength by 70% in one study
- Mixed results. Some equine studies show benefit, others show no difference vs saline
- Limited mechanistic studies; mostly clinical case series
- TB-500 has the strongest equine data; BPC-157 shows promise in rodent models but lacks large trials
- Human Clinical Data
- Essentially none. One uncontrolled case series in athletes
- No published human trials
- Multiple RCTs with mixed outcomes; meta-analyses show modest benefit for certain conditions
- Decades of clinical use but weak evidence base
- PRP is the only option with human RCTs, but results are inconsistent
- Typical Dosing Protocol
- 2–5mg subcutaneously twice weekly for 4–8 weeks
- 250–500mcg daily (oral or subcutaneous) for 4–6 weeks
- 3–6mL injection at injury site, 1–3 sessions spaced 2–4 weeks apart
- 12.5–25% dextrose solution, 3–6 injections spaced 2–4 weeks
- Dosing for TB-500 and BPC-157 is empirical, not evidence-based
- Regulatory Status
- Not FDA-approved for human use; banned by WADA
- Not FDA-approved; research-only in most jurisdictions
- FDA-approved device (centrifuge systems); procedure is legal but not standardized
- Legal but not FDA-regulated as a drug
- Only PRP is a mainstream medical procedure
- Bottom Line
- Strongest animal data for tendon healing but zero human trials. Mechanism is well-characterized but clinical application remains speculative
- Promising rodent data but completely unvalidated in humans. Regulatory status limits research
- The only option with human clinical trials, but outcomes vary widely depending on injury type and preparation method
- Weakest evidence base but lowest risk and cost. May work through placebo effect or minor inflammatory stimulation
- TB-500 is the most mechanistically plausible for tendon repair based on animal models, but human use is entirely off-label and unsupported by clinical trials